Has Aubrey de Grey publicly confirmed taking specific longevity drugs?

De Grey has confirmed taking supplements including NAD+ precursors in podcast and conference appearances. He has spoken favorably about senolytics and rapamycin but has not publicly detailed a specific personal protocol with doses and schedules for prescription compounds.

Are senolytics available by prescription?

Dasatinib is FDA-approved for certain leukemias and can be prescribed off-label. Quercetin is available over the counter as a supplement. The combination has not been approved for anti-aging use. Off-label prescribing of dasatinib for longevity should involve a physician familiar with its side effect profile, including risks of fluid retention and pulmonary complications.

What is the SENS framework?

SENS stands for Strategies for Engineered Negligible Senescence. It categorizes aging damage into seven types (mitochondrial mutations, intracellular junk, extracellular junk, cell loss, cell senescence, extracellular crosslinks, and nuclear mutations) and proposes a repair strategy for each. De Grey has argued that addressing all seven would effectively halt biological aging.

Is rapamycin safe for healthy people to take for longevity?

No completed randomized trial has established the safety and efficacy of rapamycin for longevity in healthy humans. Known side effects at immunosuppressive doses include elevated cholesterol, insulin resistance, and susceptibility to infections. Low-dose intermittent protocols may carry a different risk profile, but this remains under active investigation.

What does Aubrey de Grey's LEV Foundation research?

The Longevity Escape Velocity Foundation funds mouse lifespan studies testing combinations of longevity interventions. The goal is to achieve "strong mouse rejuvenation," defined as doubling the remaining lifespan of middle-aged mice, which de Grey argues would accelerate human translation timelines.

Aubrey de Grey Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Who: Aubrey de Grey, Ph.D., biomedical gerontologist and co-founder of the SENS Research Foundation
Drug family: Longevity (multiple compound classes)
Status: Confirmed public advocacy and self-reported personal experimentation with longevity compounds
Key compounds discussed publicly: Senolytics, NAD+ precursors, rapamycin-class mTOR inhibitors
The HealthRX Medical Team angle: De Grey's public record offers a rare case study of a trained scientist narrating his own relationship with experimental longevity interventions in real time

Who Is Aubrey de Grey?

Aubrey de Grey earned his Ph.D. in biology from the University of Cambridge in 2000 and spent the following two decades as arguably the most visible advocate for treating aging as an engineering problem. He co-founded the SENS Research Foundation in 2009, building a research agenda around seven categories of cellular and molecular damage that accumulate with age. His 2007 book Ending Aging laid out the thesis that each damage type could, in principle, be repaired or rendered harmless.

His public profile grew through hundreds of conference talks, podcast appearances on shows like the Joe Rogan Experience and Lex Fridman's podcast, and media coverage from outlets including BBC News and WIRED. Throughout these appearances, de Grey has discussed his personal approach to longevity in broad terms, making him one of the few academic researchers who has been willing to narrate his own self-experimentation publicly.

The Public Timeline: What de Grey Has Actually Said

Pre-2010: The beer-and-don't-worry era. In early interviews, de Grey was notably casual about his own health practices. He told multiple interviewers that he drank significant quantities of beer, did not exercise deliberately, and relied on what he called a "genetic advantage" for his relatively lean frame. This period is well documented in profiles from The Guardian and similar outlets.

2010 to 2018: Gradual shift toward personal supplementation. As the SENS Foundation funded research into mitochondrial mutations, intracellular aggregates, and senescent cell clearance, de Grey began referencing his own supplement regimen in conference Q&A sessions. He mentioned taking standard micronutrient supplements and expressed growing interest in NAD+ precursor compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). He stopped short of detailing doses or specific products in most public forums.

2019 to 2022: Senolytic advocacy intensifies. De Grey's public commentary increasingly emphasized senolytics, the class of drugs designed to selectively eliminate senescent cells. In podcast appearances during this period, he referenced the landmark dasatinib-plus-quercetin mouse study published in Aging Cell in 2015 and discussed the translational potential of these compounds. While he spoke about senolytics as a researcher, he also indicated in several interviews that he considered them part of a reasonable personal longevity strategy, though he did not disclose specific personal protocols.

2023 to present: The Longevity Escape Velocity Foundation era. After departing SENS, de Grey launched the Longevity Escape Velocity (LEV) Foundation, which funds mouse lifespan studies testing combination interventions. In interviews with the LEV Foundation's own media channels and external podcasts, he has discussed the rationale for combining senolytics, rapamycin-class mTOR inhibitors, and other compounds in aging mice. He has acknowledged taking "a few things" personally but consistently frames his own regimen as secondary to the research agenda.

Clinical Context: The Compounds de Grey Champions

Senolytics (Dasatinib + Quercetin)

Senescent cells accumulate with age and secrete a pro-inflammatory cocktail known as the senescence-associated secretory phenotype (SASP). The combination of dasatinib (a tyrosine kinase inhibitor approved for leukemia) and quercetin (a plant flavonoid) was shown in 2015 to clear senescent cells in mice, extending healthspan and reducing age-related pathology (Zhu et al., Aging Cell, 2015).

In humans, a small pilot study in patients with idiopathic pulmonary fibrosis showed the combination was feasible and reduced senescent cell markers over three weeks of intermittent dosing (Justice et al., EBioMedicine, 2019). Larger trials remain ongoing. Dasatinib carries FDA black-box warnings for pulmonary arterial hypertension and pleural effusions, which is why the HealthRX Medical Team emphasizes that off-label senolytic use without physician oversight carries real risk.

NAD+ Precursors (NR and NMN)

NAD+ levels decline with age, and restoring them has been proposed as a way to support mitochondrial function and DNA repair. Nicotinamide riboside and nicotinamide mononucleotide both raise blood NAD+ levels in human studies (Martens et al., Nature Communications, 2018). Whether this translates into measurable lifespan or healthspan extension in humans remains unproven. A 2024 clinical trial of NMN showed improvements in some biomarkers of aging but no hard clinical endpoints (Yi et al., GeroScience).

De Grey has publicly acknowledged taking NAD+ precursors while noting that the evidence base is still "early stage." The HealthRX Medical Team considers this an honest framing. These compounds appear safe at studied doses (typically 250 to 1 to 000 mg/day for NR), but the gap between "raises a biomarker" and "extends healthy life" is not yet closed.

mTOR Inhibition (Rapamycin and Rapalogs)

Rapamycin remains the most replicated lifespan-extending drug in mammalian studies. The Interventions Testing Program showed rapamycin extended median lifespan in genetically heterogeneous mice by 10 to 15%. De Grey has cited this data extensively and the LEV Foundation is funding combination studies that include rapamycin-class compounds.

In humans, rapamycin is FDA-approved as an immunosuppressant for organ transplant recipients and carries well-characterized side effects: hyperlipidemia, impaired glucose tolerance, mouth ulcers, and increased infection risk. Low-dose, intermittent rapamycin protocols are being explored for longevity purposes, but no completed randomized trial has demonstrated lifespan extension in humans. A trial by the AgelessRx group (the PEARL trial) is evaluating low-dose rapamycin's effects on aging biomarkers.

De Grey has spoken favorably about rapamycin's potential but, to public knowledge, has not confirmed personal use. The HealthRX Medical Team notes that this distinction matters: enthusiasm for a compound's preclinical data is not the same as a personal endorsement for unsupervised use.

The HealthRX Medical Team Take

Aubrey de Grey occupies an unusual position in longevity discourse. He is not a lifestyle influencer selling a supplement stack. He is a trained researcher whose career has been spent arguing that aging is a damage-accumulation process amenable to periodic repair. His public statements about personal experimentation are notably restrained compared to many figures in the longevity space. He discusses compound classes and mechanisms rather than brands and doses.

That restraint is appropriate. The compounds he champions (senolytics, NAD+ precursors, mTOR modulators) all have genuine preclinical support, but none has cleared the bar of a completed, adequately powered human trial showing lifespan or major healthspan extension. The HealthRX Medical Team recognizes de Grey's contribution to making these therapies subjects of serious research funding. We also recognize that the gap between "promising mouse data" and "safe, effective human intervention" is where the most important clinical work still needs to happen.

For individuals inspired by de Grey's advocacy, the clinical recommendation is straightforward. Work with a physician who understands these compound classes. Do not extrapolate mouse dosing to human dosing without medical guidance. Monitor liver enzymes, lipid panels, complete blood counts, and fasting glucose if experimenting with rapamycin or dasatinib. And understand that even the most promising longevity compounds are, as of 2026, investigational in the anti-aging context.

Frequently asked questions

›

References

Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. pubmed.ncbi.nlm.nih.gov/25754370
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. pubmed.ncbi.nlm.nih.gov/30616998
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. pubmed.ncbi.nlm.nih.gov/29514064
Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. pubmed.ncbi.nlm.nih.gov/24835147
FDA Prescribing Information: Dasatinib (Sprycel). accessdata.fda.gov